Mitogen-activated protein kinase kinase 1 mRNA 3' untranslated region (MEK1 mRNA 3' UTR)

The Mitogen-activated protein kinase kinase 1 (MEK1) mRNA 3' untranslated region (UTR) is a critical non-coding segment of the MAP2K1 transcript that governs the post-transcriptional fate of the message (NCBI Gene: 5604). This region contains specific binding sites for microRNAs, such as miR-424 and miR-1, as well as various RNA-binding proteins that collectively determine mRNA stability, localization, and translation efficiency (PubMed: 25613344, PubMed: 21822215). MEK1 is a central kinase within the MAPK/ERK signaling pathway, which is a primary regulator of cell proliferation, differentiation, and survival (UniProt: Q02750). Dysregulation or overexpression of MEK1 is a hallmark of many malignancies, including melanoma and colorectal cancer, and is also implicated in developmental disorders known as RASopathies. While traditional therapies focus on inhibiting the MEK1 protein's catalytic activity, targeting the 3' UTR with antisense oligonucleotides (ASOs) or miRNA mimics offers a strategy to reduce MEK1 protein synthesis at the source. This approach may help overcome resistance mechanisms associated with kinase domain mutations by inducing transcript degradation or blocking translation. Consequently, the MEK1 mRNA 3' UTR represents a high-value target for precision medicine in oncology and genetic disease management.

Other names

MAP2K1 mRNA 3' UTRMAP kinase kinase 1 mRNA 3' UTRMKK1 mRNA 3' UTRMAPK/ERK kinase 1 mRNA 3' untranslated region

Antisense-mediated mRNA degradation via RNase H recruitment or RNA interference-mediated translational repression and transcript decay by targeting regulatory motifs within the 3' UTR (PubMed: 25613344, PubMed: 21822215).